Total Payments
$759.33
2024 Payments
$410.37
Companies
9
Transactions
15
Medicare Patients
1,811
Medicare Billing
$2.5M
Payment Breakdown by Category
Education$391.95 (51.6%)
Food & Beverage$367.38 (48.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $391.95 | 4 | 51.6% |
| Food and Beverage | $367.38 | 11 | 48.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $391.95 | 4 | $0 (2024) |
| Merck Sharp & Dohme LLC | $117.48 | 2 | $0 (2023) |
| Kite Pharma, Inc. | $95.58 | 1 | $0 (2022) |
| UCB, Inc. | $40.59 | 2 | $0 (2021) |
| GlaxoSmithKline, LLC. | $36.67 | 2 | $0 (2021) |
| Biogen, Inc. | $22.08 | 1 | $0 (2021) |
| ARRAY BIOPHARMA INC | $21.87 | 1 | $0 (2023) |
| EMD Serono, Inc. | $18.42 | 1 | $0 (2024) |
| Amgen Inc. | $14.69 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $410.37 | 5 | Astellas Pharma US Inc ($391.95) |
| 2023 | $139.35 | 3 | Merck Sharp & Dohme LLC ($117.48) |
| 2022 | $95.58 | 1 | Kite Pharma, Inc. ($95.58) |
| 2021 | $114.03 | 6 | UCB, Inc. ($40.59) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/22/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $18.42 | General |
| 04/25/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 03/25/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.95 | General |
| 03/25/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $95.00 | General |
| 03/05/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $98.00 | General |
| 09/22/2023 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: ONCOLOGY | ||||||
| 08/18/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $93.55 | General |
| Category: ONCOLOGY | ||||||
| 10/12/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $95.58 | General |
| Category: CELLT | ||||||
| 03/24/2021 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: Bone Health | ||||||
| 03/16/2021 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: IMMUNOLOGY | ||||||
| 03/08/2021 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: Immunology | ||||||
| 02/02/2021 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $22.08 | General |
| 01/26/2021 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: IMMUNOLOGY | ||||||
| 01/04/2021 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 353 | 548 | $160,744 | $55,748 |
| 2022 | 3 | 356 | 468 | $105,624 | $41,706 |
| 2021 | 13 | 427 | 13,750 | $2.6M | $277,675 |
| 2020 | 14 | 675 | 67,744 | $15.3M | $2.1M |
Total Patients
1,811
Total Services
82,510
Medicare Billing
$2.5M
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 235 | 409 | $117,790 | $37,650 | 32.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 118 | 139 | $42,954 | $18,098 | 42.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 182 | 259 | $59,554 | $23,491 | 39.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 74 | 88 | $27,194 | $11,144 | 41.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 100 | 121 | $18,876 | $7,070 | 37.5% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2021 | 26 | 2,640 | $1.1M | $91,842 | 8.6% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2021 | 11 | 1,675 | $428,633 | $71,410 | 16.7% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2021 | 17 | 6,720 | $302,467 | $44,196 | 14.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 36 | 2,160 | $195,437 | $32,704 | 16.7% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 61 | 110 | $333,960 | $11,381 | 3.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 80 | 106 | $24,374 | $10,074 | 41.3% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2021 | 70 | 123 | $207,624 | $7,067 | 3.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 53 | 66 | $10,296 | $4,399 | 42.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 17 | 18 | $5,562 | $2,402 | 43.2% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2021 | 19 | 41 | $26,051 | $902.70 | 3.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 13 | 15 | $22,572 | $675.09 | 3.0% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2021 | 11 | 55 | $3,682 | $373.34 | 10.1% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 13 | 21 | $9,135 | $248.82 | 2.7% |
| J3357 | Ustekinumab, for subcutaneous injection, 1 mg | Office | 2020 | 19 | 3,420 | $2.8M | $508,299 | 18.0% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2020 | 40 | 12,030 | $4.3M | $502,873 | 11.7% |
| J9312 | Injection, rituximab, 10 mg | Office | 2020 | 19 | 5,250 | $2.5M | $380,887 | 15.5% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2020 | 14 | 5,925 | $1.4M | $259,654 | 18.2% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2020 | 39 | 32,130 | $1.4M | $230,500 | 16.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 100 | 7,320 | $635,269 | $113,126 | 17.8% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 98 | 481 | $1.2M | $47,603 | 3.8% |
About Ginger Carmichael
Ginger Carmichael is a Oncology healthcare provider based in Santa Maria, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2018. The National Provider Identifier (NPI) number assigned to this provider is 1760974018.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ginger Carmichael has received a total of $759.33 in payments from pharmaceutical and medical device companies, with $410.37 received in 2024. These payments were reported across 15 transactions from 9 companies. The most common payment nature is "Education" ($391.95).
As a Medicare-enrolled provider, Carmichael has provided services to 1,811 Medicare beneficiaries, totaling 82,510 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Oncology
- Other Specialties Nurse Practitioner, Nurse Practitioner
- Location Santa Maria, CA
- Active Since 06/02/2018
- Last Updated 11/02/2023
- Taxonomy Code 163WX0200X
- Entity Type Individual
- NPI Number 1760974018
Products in Payments
- Yescarta (Drug) $95.58
- LYNPARZA (Biological) $93.55
- Cimzia (Drug) $40.59
- BENLYSTA (Biological) $36.67
- KEYTRUDA (Biological) $23.93
- XALKORI (Drug) $21.87
- EVENITY (Biological) $14.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.